Yi Hong Yao
Chief Tech/Sci/R&D Officer bei CELLULAR BIOMEDICINE GROUP, INC.
Profil
Yi Hong Yao is currently the Chief Scientific Officer at AbelZeta Pharma, Inc. Prior to this, he worked as a Director at Medimmune, Inc. from 2011 to 2015.
Dr. Yao received his graduate degree from Boston University, his doctorate from the University of Kansas, and his undergraduate degree from Fudan University.
Aktive Positionen von Yi Hong Yao
| Unternehmen | Position | Beginn |
|---|---|---|
| CELLULAR BIOMEDICINE GROUP, INC. | Chief Tech/Sci/R&D Officer | 01.08.2015 |
Ehemalige bekannte Positionen von Yi Hong Yao
| Unternehmen | Position | Ende |
|---|---|---|
| Medimmune, Inc. | Director/Board Member | 01.07.2015 |
Ausbildung von Yi Hong Yao
| Boston University | Graduate Degree |
| University of Kansas | Doctorate Degree |
| Fudan University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
AbelZeta Pharma, Inc.
 AbelZeta Pharma, Inc. BiotechnologyHealth Technology Cellular Biomedicine Group, Inc. is a holding company, which engages in the development of new treatments for cancerous and degenerative diseases utilizing proprietary cell-based technologies. It specializes in immune cell therapy. The company was founded in 2009 and is headquartered in Rockville, MD. | Health Technology |
| Medimmune, Inc. | Health Technology |
